Hopp Pharmaceutical

Hopp Pharmaceutical is a biotechnology company based in Suzhou, China, specializing in the development of innovative therapeutics through Targeted Protein Degradation (TPD). The company utilizes its proprietary PROTAC (Proteolysis Targeting Chimera) and molecular glue platforms to target proteins previously considered undruggable, particularly in the field of oncology. Its lead development programs include HP-001, an Androgen Receptor (AR) degrader for prostate cancer, and HP-002, an Estrogen Receptor (ER) degrader for breast cancer. Hopp Pharmaceutical leverages a specialized library of E3 ligase ligands to design highly selective and potent small molecule degraders. The company aims to address clinical challenges such as drug resistance in solid tumors by providing precision medicine solutions. Founded in 2020, Hopp Pharmaceutical is backed by prominent venture capital firms and is actively advancing its pipeline through preclinical stages.